Mark T Dransfield1, Andrew M Wilhelm2, Brian Flanagan3, Clifford Courville3, Sherry L Tidwell4, S Vamsee Raju4, Amit Gaggar4, Chad Steele4, Li Ping Tang5, Bo Liu5, Steven M Rowe6. 1. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL; Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL. Electronic address: mdrans99@uab.edu. 2. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL. 3. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL. 4. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL; Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL. 5. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL. 6. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL; UAB Lung Health Center, University of Alabama at Birmingham, Birmingham, AL; Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL.
Abstract
BACKGROUND: Cigarette smoke and smoking-induced inflammation decrease cystic fibrosis transmembrane conductance regulator (CFTR) activity and mucociliary transport in the nasal airway and cultured bronchial epithelial cells. This raises the possibility that lower airway CFTR dysfunction may contribute to the pathophysiology of COPD. We compared lower airway CFTR activity in current and former smokers with COPD, current smokers without COPD, and lifelong nonsmokers to examine the relationships between clinical characteristics and CFTR expression and function. METHODS: Demographic, spirometry, and symptom questionnaire data were collected. CFTR activity was determined by nasal potential difference (NPD) and lower airway potential difference (LAPD) assays. The primary measure of CFTR function was the total change in chloride transport (Δchloride-free isoproterenol). CFTR protein expression in endobronchial biopsy specimens was measured by Western blot. RESULTS: Compared with healthy nonsmokers (n = 11), current smokers (n = 17) showed a significant reduction in LAPD CFTR activity (Δchloride-free isoproterenol, -8.70 mV vs -15.9 mV; P = .003). Similar reductions were observed in smokers with and without COPD. Former smokers with COPD (n = 7) showed a nonsignificant reduction in chloride conductance (-12.7 mV). A similar pattern was observed for CFTR protein expression. Univariate analysis demonstrated correlations between LAPD CFTR activity and current smoking, the presence of chronic bronchitis, and dyspnea scores. CONCLUSIONS: Smokers with and without COPD have reduced lower airway CFTR activity compared with healthy nonsmokers, and this finding correlates with disease phenotype. Acquired CFTR dysfunction may contribute to COPD pathogenesis.
BACKGROUND: Cigarette smoke and smoking-induced inflammation decrease cystic fibrosis transmembrane conductance regulator (CFTR) activity and mucociliary transport in the nasal airway and cultured bronchial epithelial cells. This raises the possibility that lower airway CFTR dysfunction may contribute to the pathophysiology of COPD. We compared lower airway CFTR activity in current and former smokers with COPD, current smokers without COPD, and lifelong nonsmokers to examine the relationships between clinical characteristics and CFTR expression and function. METHODS: Demographic, spirometry, and symptom questionnaire data were collected. CFTR activity was determined by nasal potential difference (NPD) and lower airway potential difference (LAPD) assays. The primary measure of CFTR function was the total change in chloride transport (Δchloride-free isoproterenol). CFTR protein expression in endobronchial biopsy specimens was measured by Western blot. RESULTS: Compared with healthy nonsmokers (n = 11), current smokers (n = 17) showed a significant reduction in LAPD CFTR activity (Δchloride-free isoproterenol, -8.70 mV vs -15.9 mV; P = .003). Similar reductions were observed in smokers with and without COPD. Former smokers with COPD (n = 7) showed a nonsignificant reduction in chloride conductance (-12.7 mV). A similar pattern was observed for CFTR protein expression. Univariate analysis demonstrated correlations between LAPD CFTR activity and current smoking, the presence of chronic bronchitis, and dyspnea scores. CONCLUSIONS: Smokers with and without COPD have reduced lower airway CFTR activity compared with healthy nonsmokers, and this finding correlates with disease phenotype. Acquired CFTR dysfunction may contribute to COPD pathogenesis.
Authors: T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger Journal: Am J Respir Crit Care Med Date: 1995-12 Impact factor: 21.405
Authors: Jennifer S Guimbellot; James A Fortenberry; Gene P Siegal; Bryan Moore; Hui Wen; Charles Venglarik; Yiu-Fai Chen; Suzanne Oparil; Eric J Sorscher; Jeong S Hong Journal: Am J Respir Cell Mol Biol Date: 2008-05-12 Impact factor: 6.914
Authors: James C Hogg; Fanny S F Chu; Wan C Tan; Don D Sin; Sanjay A Patel; Peter D Pare; Fernando J Martinez; Robert M Rogers; Barry J Make; Gerard J Criner; Reuben M Cherniack; Amir Sharafkhaneh; James D Luketich; Harvey O Coxson; W Mark Elliott; Frank C Sciurba Journal: Am J Respir Crit Care Med Date: 2007-06-07 Impact factor: 21.405
Authors: Clifford A Courville; S Vamsee Raju; Bo Liu; Frank J Accurso; Mark T Dransfield; Steven M Rowe Journal: Am J Respir Crit Care Med Date: 2015-12-15 Impact factor: 21.405
Authors: Vivian Y Lin; Matthew D Fain; Patricia L Jackson; Taylor F Berryhill; Landon S Wilson; Marina Mazur; Stephen J Barnes; J Edwin Blalock; S Vamsee Raju; Steven M Rowe Journal: Am J Respir Cell Mol Biol Date: 2019-08 Impact factor: 6.914
Authors: Elise Blanchard; Lorna Zlock; Anna Lao; Delphine Mika; Wan Namkung; Moses Xie; Colleen Scheitrum; Dieter C Gruenert; Alan S Verkman; Walter E Finkbeiner; Marco Conti; Wito Richter Journal: FASEB J Date: 2013-11-07 Impact factor: 5.191
Authors: George M Solomon; Inez Bronsveld; Kathryn Hayes; Michael Wilschanski; Paola Melotti; Steven M Rowe; Isabelle Sermet-Gaudelus Journal: J Vis Exp Date: 2018-09-13 Impact factor: 1.355
Authors: S Vamsee Raju; Patricia L Jackson; Clifford A Courville; Carmel M McNicholas; Peter A Sloane; Gina Sabbatini; Sherry Tidwell; Li Ping Tang; Bo Liu; James A Fortenberry; Caleb W Jones; Jeremy A Boydston; J P Clancy; Larry E Bowen; Frank J Accurso; J Edwin Blalock; Mark T Dransfield; Steven M Rowe Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe Journal: JCI Insight Date: 2016-09-22